JBT is a clinical stage biopharmaceutical company developing a non-psychotropic synthetic derivative of THC, the active ingredient in marijuana. The first indication being pursued is scleroderma, a multibillion dollar orphan indication with high mortality and effective therapies. Due to prior investments in the clinical development of AJA for a different indication, JBT is able to reach a high ROI exit in 18 months with a $1.5M investment